Objectives: To determine the usefulness of flucloxacillin as empirical therapy for putative Staphylococcus aureus infections in intensive care unit (ICU) patients in the Netherlands, the antibiotic resistance of S. aureus isolates from ICUs over a 13 year period was investigated.
Introduction
Between 20% and 30% of intensive care unit (ICU)-acquired infections are caused by Staphylococcus aureus, 1, 2 which is an aetiological agent of bloodstream infections, endocarditis, soft tissue infection, osteomyelitis and pneumonia. 3 Forty percent of ICU patients receive empirical therapy. 4 The choice of empirical antibiotic treatment for ICU patients is challenging, because of the emergence of antibiotic-resistant organisms and the risk of superinfections with circulating resistant organisms. 4 As early optimal empirical therapy decreases the mortality and morbidity of ICU patients, 5 it is essential to provide the clinician with resistance data for the local circulating strains in order to optimize the empirical choice.
A national longitudinal resistance surveillance programme in specific hospital wards, including ICUs, started in 1996 in the Netherlands. This programme, from the Dutch Antibiotic Resistance Surveillance Group (SWAB), monitors at local and national levels the resistance patterns of microorganisms isolated from ICUs, and the outpatient departments of pulmonology and urology of 14 hospitals geographically spread over the Netherlands. The aim of this national surveillance programme is to provide actual antibiotic resistance data to clinicians, in order to optimize their empirical antibiotic choice, to control antibiotic use and, indirectly, to control the antibiotic resistance problem. 6 The results of 13 years of surveillance of the antimicrobial resistance of S. aureus isolated from ICU patients in the Netherlands are described.
Materials and methods
Population and study design The oxacillin-resistant isolates were analysed for the presence of the S. aureus-specific femA gene as well as the methicillin-resistant S. aureus (MRSA)-specific mecA gene using a real-time PCR assay as described previously. 9 
Statistical analysis
Data were analysed using SPSS Version 15.0. Trends over time of the prevalence of antibiotic resistance were determined by linear regression analysis; the prevalence data were weighted on the amount of isolates collected each year. The slopes of the resistance graphs are represented with the generally used symbol (m) and their respective 95% confidence intervals are given in parentheses. A P value of ,0.05 was considered statistically significant.
Results

Bacterial isolates
In total, 1146 of the 9911 (12%) ICU isolates collected during the study period were S. aureus, comprising 270 isolates from three centres in the north (24%), 267 isolates from two centres in the east (23%), 276 isolates from five centres in the west (24%) and 333 isolates from four centres in the south of the Netherlands (29%). The number of S. aureus isolates each year was: 1996, n¼ 90; 1997, n ¼ 76; 1998, n ¼ 77; 1999, n ¼70; 
Antibiotic resistance over time
The overall resistance to penicillin increased from 74% in 1996 to 75% in 2008 (P ¼0.09). Flucloxacillin-resistant strains were observed among 12 of the 1146 isolates (1.0%), which were mecA-and femA-positive and thus characterized as MRSA. Of the 12 MRSA isolates, 2 were found in 1996 (2% of the isolates in this year), 2 in 1998 (3%), 3 in 2004 (3%), 2 in 2007 (2%) and 3 in 2008 (3%). These strains were isolated in three regions and eight hospitals.
Clindamycin showed an increase in resistance from $3.0% in 1996 to 3.2% in 2008 (P ¼ 0.801; Figure 1c ) and doxycycline also showed an increase from 2.2% in 1996 to 8.2% in 2008, overall 5.6% (P ¼ 0.69; Figure 1b) .
The resistance to clarithromycin showed a significant trend over time, from 4.2% to 10 Of the 85 ciprofloxacin-resistant isolates, 46 (54%) were resistant, 23 (27%) were intermediately susceptible and 16 (19%) were susceptible to moxifloxacin.
Resistance to cephalosporins, carbapenems, rifampicin and gentamicin was sporadically observed. No resistance was found to vancomycin, teicoplanin and linezolid. One isolate was intermediately susceptible to vancomycin (MIC ¼ 4 mg/L).
Multidrug resistance
Multidrug resistance was observed in 97 isolates and the prevalence increased over time (Figure 3 ). Most frequent was resistance to the combination of penicillin, clarithromycin, clindamycin and ciprofloxacin (n ¼12). For the penicillinsusceptible isolates, the most common combination was resistance to clarithromycin, clindamycin and doxycycline (n ¼ 22). Six MRSA strains were resistant to five or more antibiotic groups. None of the isolates was resistant to all antibiotics tested.
Discussion
The finding of 1% flucloxacillin resistance among the clinical S. aureus isolates from ICU patients over a 13 year period still justifies the empirical therapy choice of flucloxacillin in the case of a putative S. aureus infection in these patients in the Netherlands. It may be combined with gentamicin in the case of a life-threatening infection and/or rifampicin in the presence of a foreign body.
ICU-acquired infections are often caused by antibioticresistant microorganisms. Several factors, such as frequent use of broad-spectrum antibiotics, invasive procedures, underlying diseases, crowding of patients and transmission of resistant bacteria between patients, contribute to the high risk of an ICU as an area for the emergence and spread of antibiotic resistance. 10 -12 Therefore, especially in the ICU setting, the choice of empirical antimicrobial therapy for critically ill patients is challenging. 13 Optimal choice of the empirical antibiotic prescription is important to improve the outcome of the infections, to reduce the patients' morbidity and mortality, and to contribute to the control of the emergence of antibiotic resistance. 14 As adequate therapy without delay is crucial for the outcome and because the microbiological laboratory cannot support the clinician within the timeframe provided with antibiotic resistance data of the causative microorganism(s), the physicians have to rely on epidemiological data. Surveillance studies can provide clinicians with actual epidemiological data and thus support the optimal antibiotic choice for empirical therapy. 13 -15 In 1996, the SWAB surveillance programme started in the Netherlands, which is different from other surveillance programmes. First, the participating hospitals are distributed over the country, covering !25% of the total Dutch population. Second, all susceptibility testing methods are quantitatively performed in one reference laboratory. Third, the data of several years are available, which allows us to follow the development of resistance over time.
Recently, the CARE-ICU surveillance project started in eight European countries. The aim of this project was, among others, to control the emergence of microbial resistance by judicious use of antibiotics. The first report after 1 year of surveillance mentioned a variation in the prevalence of resistance and antibiotic consumption between countries. 15 Resistance to methicillin among S. aureus isolates ranged per country from 0% to 100%, with a median of 11.6%. One of the limitations of this surveillance is the low number of participating ICUs per country, mostly four or less. Several studies described a higher prevalence of antimicrobial resistance in ICU patients compared with patients from other hospital wards and the community, 12, 16, 17 due to high antibiotic use in ICU settings and critically ill patients. 4 ,18 However, we found no significant differences in resistance to vancomycin, linezolid, teicoplanin, cephalosporins, carbapenems and flucloxacillin between ICU isolates and the isolates from other wards of the hospitals or the community. 6 Significant differences (P, 0.05) in resistance between the isolates from the community and the ICU patients were observed for penicillin (71% versus 75%), tetracycline (4% versus 6%), clarithromycin (4% versus 8%) and ciprofloxacin (1% versus 12%), respectively.
6 A significant difference in resistance to ciprofloxacin was also observed between hospital and ICU patients (7% versus 12%).
6 No differences in resistance to clarithromycin and penicillin were observed between hospitals and ICU patients. Low antibiotic resistance percentages of S. aureus from ICU patients, for example flucloxacillin resistance ,2%, were also observed in Swedish ICUs over a 5 year period. 19 -21 A recent systematic review and meta-analysis by Tacconelli et al. 22 showed clear associations between exposure to fluoroquinolones, glycopeptides and b-lactam antibiotics and the prevalence of MRSA. Antibiotic use in both Sweden and the Netherlands is relatively low compared with other European countries. 19 This, in combination with the search-and-destroy policy as applied for MRSA in the Netherlands, is very likely the main reason for the low prevalence of MRSA in this country. 20 According to the European Antibiotic Resistance Surveillance Study (EARSS) data, the prevalence of MRSA in the Netherlands increased from 0.3% in 1999 to 1.4% in 2007, whereas in the present study no increase was observed. 21 The difference in prevalence might be due to differences in the source of the isolates. Although one might expect a higher MRSA percentage in ICU patients, this hypothesis was not confirmed by the data from this study. There are several reasons that could lead to differences in results between our study and the EARSS study: (i) our study includes all intensive care isolates, while the EARSS study only includes invasive isolates (blood culture and CSF isolates); (ii) we only include one isolate per patient, while the EARSS study includes invasive isolates-this can lead to a selection bias when more than one isolate per patient is included; and (iii) both studies include different hospitals and differences in the prevalence of MRSA between hospitals in the same country do exist.
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Although the percentage resistance to most antibiotics remained ,10% over the years of study (except for penicillin), a significant increase in resistance was observed for clarithromycin, moxifloxacin and ciprofloxacin. Overall, the increase in resistance to moxifloxacin was lower than for ciprofloxacin and started later, because moxifloxacin was available from 1998 23 and ciprofloxacin was obtainable 10 years earlier. Between both compounds, a partial cross-resistance has been described-a double mutation in grlA and gyrA is required for moxifloxacin resistance compared with a single mutation for ciprofloxacin resistance. 24, 25 This was confirmed by the data from the present study for the ciprofloxacin-resistant isolates, which showed that 19% of the ciprofloxacin isolates were still susceptible to moxifloxacin and .50% of the strains were resistant to both agents.
Ciprofloxacin has a low intrinsic activity against S. aureus (MIC 90 0.5-1 mg/L) and, therefore, it was never the drug of first choice for S. aureus infections in the Netherlands. 5 Since the resistance percentage is .10%, it cannot be used as empirical therapy in these infections.
The emergence of multidrug resistance needs consideration. Resistance to three or more antimicrobial groups was found in 8% of the isolates and increased over time. This phenomenon was sporadically found in the northern part of the Netherlands, which may be explained by the absence of a participating university hospital.
In conclusion, based on the antibiotic susceptibility data of ICU isolates collected over more than a decade, the empirical therapy for putative S. aureus infections in ICU patients in the Netherlands is still flucloxacillin, with or without gentamicin.
